ABBVIE INC. (ABBV) Stock Price

ABBVStock

$265.79+25.60%52W

Market Cap$469.68B

P/E104.88x

PEG Ratio0.43

Div yield4.47%

Beta0.22

ABBV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)4.41%

Price vs S&P 500 (4W)-2.55%

PEG Ratio0.43

VGM Score53.51

P/E Ratio (Annual)104.88x

Indicated Dividend Yield (Annual)4.47%

P/CF (Annual)23.29x

Book Value / Share (Quarterly)$0.80

P/TBV (Annual)455.35x

Indicated Dividend (Annual)$6.92

Revenue Growth (3Y)1.75%

Cash Flow / Share (Quarterly)$10.31

Payout Ratio (TTM)189.83%

Price vs S&P 500 (YTD)3.81%

Gross Margin (TTM)72.79%

Net Profit Margin (TTM)9.80%

EPS (TTM)$3.56

10-Day Avg Trading Volume4.63M

EPS Excl Extra (TTM)$3.56

Revenue Growth (5Y)5.95%

EPS (Annual)$2.38

Dividend / Share (Annual)$6.60

ROI (Annual)6.07%

Gross Margin (Annual)71.62%

Net Profit Margin (5Y Avg)12.88%

Cash / Share (Quarterly)$3.72

P/E Basic Excl Extra (TTM)70.24x

Revenue Growth QoQ (YoY)10.16%

EPS Growth (5Y)-2.88%

P/E Normalized (Annual)104.88x

ROA (Last FY)3.15%

Revenue Growth TTM (YoY)10.39%

EBITD / Share (TTM)$9.95

ROE (5Y Avg)70.88%

Operating Margin (TTM)26.20%

Cash Flow / Share (Annual)$10.08

P/B Ratio312.13x

P/B Ratio (Quarterly)261.01x

Net Income / Employee (Annual)$74,100

EV / Revenue (TTM)7.88x

Net Interest Coverage (TTM)3.46x

ROA (TTM)4.68%

EPS Growth QoQ (YoY)285.22%

EV / EBITDA (TTM)28.76x

EPS Incl Extra (Annual)$2.38

Current Ratio (Annual)0.67x

Quick Ratio (Quarterly)0.49x

3-Month Avg Trading Volume6.58M

52-Week Price Return25.60%

EV / Free Cash Flow (Annual)28.48x

P/E Incl Extra (TTM)70.24x

Revenue / Employee (TTM)$1,129,600

Tangible BV / Share (Quarterly)$0.14

P/S Ratio (Annual)7.25x

Asset Turnover (Annual)0.46x

52-Week High$267.47

Operating Margin (5Y Avg)25.49%

EPS Excl Extra (Annual)$2.38

CapEx CAGR (5Y)8.75%

26-Week Price Return15.65%

Quick Ratio (Annual)0.41x

13-Week Price Return23.32%

Total Debt / Equity (Annual)20.19x

Current Ratio (Quarterly)0.81x

Enterprise Value$507.48B

Revenue / Share Growth (5Y)4.73%

Asset Turnover (TTM)0.48x

Book Value / Share Growth (5Y)-10.06%

Revenue / Employee (Annual)$1,073,000

Inventory Turnover (Annual)3.80x

Pretax Margin (Annual)10.79%

Cash / Share (Annual)$2.97

3-Month Return Std Dev29.00%

Gross Margin (5Y Avg)69.76%

Net Income / Employee (TTM)$110,700

EBITDA CAGR (5Y)5.65%

EBITDA Interim CAGR (5Y)7.38%

ROE (Last FY)128.66%

Net Interest Coverage (Annual)4.25x

EPS Basic Excl Extra (Annual)$2.38

P/FCF (TTM)24.34x

Receivables Turnover (TTM)4.87x

EV / Free Cash Flow (TTM)27.87x

Total Debt / Equity (Quarterly)49.22x

EPS Incl Extra (TTM)$3.56

Receivables Turnover (Annual)5.20x

ROI (TTM)5.66%

Dividend Growth Rate (5Y)6.76%

P/S Ratio (TTM)6.88x

Pretax Margin (5Y Avg)15.04%

Revenue / Share (Annual)$34.50

Tangible BV / Share (Annual)$0.14

Forward P/E16.77x

Free OCF CAGR (5Y)1.19%

Price vs S&P 500 (52W)7.29%

P/E Ratio (TTM)70.24x

EPS Growth TTM (YoY)67.60%

Year-to-Date Return15.77%

5-Day Price Return2.16%

EPS Normalized (Annual)$2.38

ROA (5Y Avg)5.27%

Net Profit Margin (Annual)6.91%

Month-to-Date Return5.41%

Cash Flow / Share (TTM)$8.66

EBITD / Share (Annual)$8.93

EPS Growth (3Y)-28.99%

Operating Margin (Annual)24.65%

LT Debt / Equity (Annual)18.14x

P/CF (TTM)22.72x

ROI (5Y Avg)8.99%

P/E Excl Extra (TTM)70.24x

LT Debt / Equity (Quarterly)45.44x

EPS Basic Excl Extra (TTM)$3.56

P/TBV (Quarterly)455.35x

Payout Ratio (Annual)275.84%

P/B Ratio (Annual)94.44x

Dividend / Share (TTM)$6.78

Inventory Turnover (TTM)3.47x

Pretax Margin (TTM)13.51%

Book Value / Share (Annual)$1.88

Price vs S&P 500 (13W)20.53%

Net Margin Growth (5Y)-7.27%

Dividend Yield (TTM)2.70%

Beta0.22x

P/FCF (Annual)24.88x

Revenue / Share (TTM)$36.36

ROE (TTM)95.59%

52-Week Low$190.75

vGradeD

gGradeC

mGradeB

vgmGradeC

ABBV Earnings Surprise History

Q2 252.97est. 2.91

Q3 251.86est. 1.78

Q4 252.71est. 2.65

Q1 262.65est. 2.67

Q2 263.65est. 3.61

ABBV Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.95

4.00

4.03

4.05

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ABBVABBVIE INC.	D	C	B	$265.79
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About ABBVIE INC.

AbbVie is a diversified pharmaceutical company with core franchises in immunology (Humira, Skyrizi, Rinvoq) and oncology (Imbruvica, Venclexta), complemented by a growing aesthetics business anchored by Botox following the 2020 Allergan acquisition. Recent 2024 acquisitions of Cerevel Therapeutics and Immunogen strengthen its neuroscience and oncology pipelines. The company's multi-therapeutic portfolio leverages established market positions and provides diversified revenue streams.